The Role of Pentraxin-3, Fetuin-A and Sirtuin-7 in the Diagnosis of Prostate Cancer

Prostate cancer is the most commonly diagnosed type of cancer and one of the leading causes of can-cer-related death in men. Numerous efforts have been made to improve existing diagnostic methods and develop a new biomarker to identify patients with prostate cancer. In line with current literature, we preferred new se-rum-based biochemical markers as Pentraxin-3, Fetuin-A and Sirtuin-7 in the present study.

A total of 174 patients aged 42-76 years were included in the study. Patients with pros-tate cancer (n = 38) were enrolled as Group 1 and patients with benign prostatic hyperplasia (n = 136) as Group 2. The serum levels of Pentraxin-3, Fetuin-A and Sirtuin-7 levels were compared between the groups.

The mean age of the patients was 61.9 ± 7.6 years (p = .001). The mean serum Prostate Specific Antigen levels 32.0 ± 59.6 (2.6-336) ng/mL and 10.0 ± 11.3 (2.5-77.4) ng/mL in Group 1 and 2, respectively (p = .029). The mean serum levels of Pentraxin-3 and Fetuin-Ain Group 1 were statistically significantlydifferent from Group 2(3.3 ± 4.4 ng/mL vs 1.8 ± 2.4 ng/mL, p = .002 and 466.8 ± 11.0 μg/mL vs 513.3 ± 11.0 μg/mL, p = .041,respec-tively). There was no significant difference between Group 1 and 2 according to serum levels of Sirtuin-7 (12.7 ± 8.2 ng/mL vs 12.7 ± 12.4 ng/mL respectively, p = .145).

Pentraxin-3, Fetuin-A and Sirtuin-7 may be effective in the diagnosis of prostate cancer in light of the current literature. In this study, it was found that Pentraxin-3 and Fetuin-A were significantly different in the diag-nosis of prostate cancer. Larger-scale prospective studies are needed to determine the importance of Pentraxin-3 and Fetuin-A in the diagnosis of prostate cancer.